Not exact matches
TORONTO, April 17 (Reuters)- Canada said on Tuesday it is working with the U.S. Food and Drug Administration to access
supplies of Mylan N.V.'s
EpiPen emergency allergy antidote amid a global shortage that has spared the United States.
TORONTO, April 17 - Canada said on Tuesday it is working with the U.S. Food and Drug Administration to access
supplies of Mylan N.V.» s
EpiPen emergency allergy antidote amid a growing shortage that has spared the United States.
And the risk of losing money also falls less on Mylan than it does on those at the end of the
supply chain, with the pharmacy having to dispense
EpiPens while accepting less in copay money upfront, then applying for a rebate and waiting to see what trickles back.
But now that the Sanofi (snynf) drug is no longer on the market — the company recalled its entire
supply last fall, and has since abandoned it — Mylan is looking to ditch contracts that constrained
EpiPen's price.
NEW YORK Mylan N.V.'s emergency allergy antidote
EpiPen is in short
supply in Canada and Britain, but remains available in the United States, the treatment's manufacturer said on Friday.
A TGA spokesman has told the newspapers that
supplies of
EpiPens will continue to be limited for a while.